The study will evaluate and compare safety and efficacy of TheraSphere vs sorafenib in hepatocellular carcinoma patients with portal vein thrombosis
At the ISET conference in January in Miami, USA, Horst Sievert, CardioVascular Center Frankfurt, Frankfurt, Germany, told delegates why he believes that renal denervation could become as important as percutaneous coronary intervention or percutaneous transluminal angioplasty. “I believe that renal denervation represents a great opportunity for interventionalists to make a difference,” he said.
In order to meet a need for transcatheter embolic agents that can be precisely placed, optimally conformed, with complete and durable occlusion, and maximal safety profile, several notable developments have occurred with respect to coil-type embolization. A generic overview of commercially available devices follows.
João Martins Pisco, professor and chair, Department of Radiology, Lisbon, Portugal, and one of the pioneers of the procedure, tells Interventional News about his personal experience with prostatic artery embolization.
The standard management of benign prostatic hyperplasia is based on the overall health of the patient, on the severity of the lower urinary tract symptoms and on quality-of-life considerations. Voiding difficulties attributable to hyperplasia can be quantified with the International Prostate Symptom Score (IPSS). Various medications can decrease the severity of voiding symptoms secondary to benign prostatic hyperplasia. Impotence, decreased libido and ejaculatory disorders are known side effects.
The European Conference on Interventional Oncology (ECIO) has announced that the meeting will become an annual event as of 2012.
Medtronic has announced that it has received a Health Canada licence for its Symplicity Renal Denervation System to reduce treatment-resistant high blood pressure in patients unresponsive to three or more anti-hypertensive medications.
First Patients Treated in Clinical Trial of Novel Medical Device Involving Interventions for Lower-Extremity Peripheral Artery Disease
Microsulis Medical has announced a multi-faceted strategic relationship with AngioDynamics, a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology.
In the Journal of Vascular and Interventional Radiology, Bart L. Dolmatch, MD, et al published findings from a study using the Fluency Plus stent graft (Bard Peripheral Vascular, Tempe, AZ) to review technical and 180-day clinical outcomes in the treatment of dysfunctional arteriovenous (AV) hemodialysis access circuits (2012;23:479-487).
The US Food and Drug Administration has given 510(k) clearance to Galil Medical to market its Visual-ICE Cryoablation System.
On 23 February 2012, Vessix Vascular announced initial patient treatments in the international multicentre REDUCE-HTN renal denervation clinical study for uncontrolled hypertension. REDUCE-HTN is a non-randomised, prospective, single cohort, 64-patient clinical study designed to validate the clinical performance of the Vessix V2 Renal Denervation System for medication-resistant hypertensive patients. Renal denervation is a new percutaneous catheter-based procedure that disrupts renal sympathetic nerves whose hyperactivity leads to abnormally high blood pressure.
SIR-Spheres microspheres (Sirtex) are safe and provide clinical benefit for patients with colon cancer liver metastases who have previously received liver-directed and systemic chemotherapy, according to the results of a prospective clinical study presented at the Society of Interventional Radiology (SIR) Annual Scientific Meeting (March 24–29, San Francisco, USA).
The results of a study presented at the Society of Interventional Radiology’s 37th Annual Scientific Meeting in San Francisco, USA, provide hope for individuals with inoperable locally advanced pancreatic cancer (LAPC). Irreversible electroporation has been successful in treating primary and metastatic liver cancer and is now in the first stages of implementation as a treatment for pancreatic cancer.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos